Immunotech Biopharm Ltd.

Immunotech Biopharm Ltd develops next‑generation T‑cell immunotherapies in China, with its flagship EAL in Phase III for post‑surgical liver cancer recurrence and a pipeline of CAR‑T, TCR‑T and niche products targeting high‑margin solid and hematologic malignancies.

Headquarters: China (CHN)

Immunotech Biopharm Ltd. Logo
Company Profile
  • Employees: 173
  • HQ: Beijing
Traded Instruments
+ Add Instrument 1
Symbol Name Type Exchange Currency ISIN Status Actions
6978 Immunotech Biopharm Ltd.
Cap: 1.6B
EQUITY HKG HKD KYG4721A1004 Active
📈
Home Login